These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2087492)

  • 1. Barrel rotation in rats induced by SMS 201-995: suppression by ceruletide.
    Ishikawa Y; Shimatsu A; Murakami Y; Imura H
    Pharmacol Biochem Behav; 1990 Nov; 37(3):523-6. PubMed ID: 2087492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329).
    Hamilton MH; Rose IC; Herberg LJ; de Belleroche JS
    Psychopharmacology (Berl); 1990; 101(3):384-9. PubMed ID: 2362955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of CCK-A receptors induces elevation of plasma corticosterone in rats.
    Katsuura G; Ibii N; Matsushita A
    Peptides; 1992; 13(1):203-5. PubMed ID: 1620654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
    Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
    Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CCK antagonist L-364,718, pancreastatin (33-49) and a somatostatin analogue on camostate-induced rat pancreatic hypertrophy.
    Schmidt WE; Stöckmann F; Choudhury AR; Wilms HM; Siegel EG; Nustede R; Fölsch UR; Creutzfeldt W
    Digestion; 1989; 44(2):105-16. PubMed ID: 2612749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of central and peripheral anorectic effects of caerulein by L-364,718.
    Leighton GE; Griesbacher T; Hill RG; Hughes J
    Eur J Pharmacol; 1989 Feb; 161(2-3):255-8. PubMed ID: 2721558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceruletide suppresses rotational behavior in lesioned rats via CCKA receptors.
    Fujisawa M; Miyamoto O; Itano T; Tokuda M; Matsui H; Nagao S; Negi T; Hatase O
    Eur J Pharmacol; 1993 Jul; 238(1):127-30. PubMed ID: 8405076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrel rotation induced by central arginine8-vasopressin treatment: involvement of neurohypophyseal peptide receptors.
    Diamant M; Baars AM; Kovács GL; De Wied D
    Pharmacol Biochem Behav; 1994 Jan; 47(1):27-32. PubMed ID: 8115425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCK-antagonist L-364,718: influence on rat pancreatic growth induced by caerulein and bombesin-like peptides.
    Schmidt WE; Choudhury AR; Siegel EG; Löser C; Conlon JM; Fölsch UR; Creutzfeldt W
    Regul Pept; 1989 Jan; 24(1):67-79. PubMed ID: 2544930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ceruletide and haloperidol on the hypothalamo-pituitary beta-endorphin system and brain beta-endorphin contents in the rat: with special reference to effects of ceruletide in chronically haloperidol-treated rats.
    Hagino Y; Okuwa M; Moroji T
    Neuropeptides; 1991 Jan; 18(1):1-14. PubMed ID: 2046884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amazing pancreas: specific regulation of pancreatic secretion of individual digestive enzymes in rats.
    Maouyo D; Morisset J
    Am J Physiol; 1995 Feb; 268(2 Pt 1):E349-59. PubMed ID: 7864113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prolonged administration of long-acting somatostatin on caerulein, CCK-8 and GRP induced pancreatic growth in the rat.
    Hajri A; Aprahamian M; Damgé C
    Regul Pept; 1991 Feb; 32(2):227-37. PubMed ID: 1709749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of peptide YY on CCK/CCK antagonist interactions in cerulein-induced pancreatic injury.
    Tito JM; Rudnicki M; Robinson DC; Guiney WB; Adrian TE; Gold MS
    Ann N Y Acad Sci; 1995 May; 757():410-2. PubMed ID: 7541974
    [No Abstract]   [Full Text] [Related]  

  • 15. The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception.
    Rattray M; Jordan CC; De Belleroche J
    Eur J Pharmacol; 1988 Jul; 152(1-2):163-6. PubMed ID: 3208830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis.
    Toriumi Y; Samuel I; Wilcockson DP; Turkelson CM; Solomon TE; Joehl RJ
    J Lab Clin Med; 1993 Oct; 122(4):450-4. PubMed ID: 8228560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
    O'Neill MF; Dourish CT; Iversen SD
    Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity.
    Akaike A; Tamura Y; Sato Y; Ozaki K; Matsuoka R; Miura S; Yoshinaga T
    Brain Res; 1991 Aug; 557(1-2):303-7. PubMed ID: 1684128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous cholecystokinin release responsible for pancreatic growth observed after pancreatic juice diversion.
    Rivard N; Guan D; Maouyo D; Grondin G; Bérubé FL; Morisset J
    Endocrinology; 1991 Dec; 129(6):2867-74. PubMed ID: 1954873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebroventricular cholecystokinin A-receptor antagonist does not reduce satiation by endogenous CCK.
    Brenner LA; Ritter RC
    Physiol Behav; 1998 Feb; 63(4):711-6. PubMed ID: 9523920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.